CD47 and neoplasm: Anti-CD47 treatment shifts the phenotype of macrophages toward the anti-tumoral subtype, leading to enhanced tumor cell phagocytosis by both anti-tumoral and pro-tumoral macrophage subtypes with a higher phagocytosis rate caused by anti-tumoral macrophages [90].